Skip to main
  1. Stocks
  2. EyePoint Pharmaceuticals
  3. Forecast
EYPT

EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

EyePoint Pharmaceuticals (EYPT) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 11%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

EyePoint is viewed favorably because management reiterated that the DME program remains on track to read out in 4Q27, and the lack of safety red flags from wet AMD supports confidence in the platform’s risk profile. The company’s DURAVYU and Durasert technology could still unlock meaningful value through positive Phase III COMO/CAPRI data, FDA openness to a wet AMD regulatory path based on pooled LUGANO/LUCIA and secondary endpoints, or a strategic partnership. Its outlook is further strengthened by the possibility of non-dilutive financing or cost reductions that could extend cash runway beyond the DME readout, preserving optionality while the pipeline advances.

Bears say

EyePoint is facing a fundamentally weakened investment case because DURAVYU has now missed non-inferiority in both pivotal wet AMD studies, with LUCIA showing a -3.7-letter adjusted treatment difference versus aflibercept and the stock falling 85% at market close after the miss. Management’s plan is still unproven, as wAMD options remain undecided while the company shifts to DME, yet that program carries the same non-inferiority framework and must overcome prior failures in wAMD and NPDR before investors regain confidence. With only $118m in cash and short-term investments, a workforce reduction of about 53%, and runway guided into 4Q27, the shares look likely to stay range-bound amid clinical and regulatory overhang until the 4Q27 readout.

EyePoint Pharmaceuticals (EYPT) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 11% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of EyePoint Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

EyePoint Pharmaceuticals (EYPT) Analyst Forecast & Price Prediction

Get the latest EyePoint Pharmaceuticals (EYPT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in EyePoint Pharmaceuticals (EYPT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About EyePoint Pharmaceuticals (EYPT) Forecast

Analysts have given EyePoint Pharmaceuticals (EYPT) a Buy based on their latest research and market trends.

According to 9 analysts, EyePoint Pharmaceuticals (EYPT) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

EyePoint Pharmaceuticals (EYPT)


EyePoint Pharmaceuticals (EYPT) Analyst Forecast & Price Prediction

Get the latest EyePoint Pharmaceuticals (EYPT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in EyePoint Pharmaceuticals (EYPT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover EYPT stock data and trends